PhysQuiz on AAN 2021: Multiple Sclerosis
Are you caught up on trials on multiple sclerosis that have been released from AAN 2021? Test your...
Read More
AAN 2021
Neurofilament light outperforms total tau as biomarker for neurodegeneration
Plasma neurofilament light chain (NfL) demonstrated to be a more valuable biomarker for neurodegeneration than total tau (T-tau) protein. This was the conclusion of the Mayo Clinic Study of Aging (MCSA), comparing the 2...
Read MoresNfL projects development of definite MS
In patients who experienced a first clinical demyelinating event, baseline levels of serum neurofilament light chain (sNfL), a biomarker of neural damage, were associated with conversion to McDonald 2005 multiple sclerosis (MS)....
Read MoreMast cell and neutrophil involvement in the disease activity of MS
Preliminary results of a genome-wide-association study (GWAS) show a possible involvement of mast cells and neutrophils in the disease activity of relapsing-remitting MS patients [1]. These results provide important knowledge on...
Read MoreThe role of brain ATP abnormalities in MS disease progression
A 3-year prospective observational study investigating ATP changes in MS via T7 MRSI, comparing patients with and without vascular disease risk factors (VDRF), demonstrated that VDRF-positive patients had lower brain ATP rates...
Read MoreMS disease-modifying therapies influence COVID-19 infection severity
MS patients treated with anti-CD20 therapies ocrelizumab and rituximab have an increased risk of severe COVID-19 infection, whereas treatment with interferon or teriflunomide could reduce that risk. These were the preliminary...
Read MoreAAN 2021: Central & Peripheral Neurological Symptoms in PIMS-TS
Despite reports of neurological manifestations in both children and adults with COVID-19, the neurological manifestations of children with recently described severe post‐infectious immune‐mediated disorder pediatric inflammatory...
Read MoreAAN 2021: Depression & Anxiety Inversely Associated With Alzheimer’s Disease Age of Onset
While evidence indicates depression as a risk factor for Alzheimer’s disease (AD) that may accelerate development and progression, the effects of other psychiatric disease on AD as less well known. For a study, researchers...
Read MoreAAN 2021: Plasma Neurofilament Light a Solid Prognostic Marker of Neurodegeneration
Previous studies indicate that elevated plasma total tau (T-tau) and neurofilament light (NfL) are, cross-sectionally and longitudinally, associated with worse cognition and neuroimaging measures of cortical thickness, cortical...
Read MoreAAN 2021: Neurological Dysfunction Negatively Impacts COVID-19 Outcomes
Although emerging data indicate that various neurological symptoms are associated with COVID-19, data are lacking on the outcomes of patients with neurological dysfunctions who acquire COVID-19. To determine these outcomes,...
Read MoreAAN 2021: Telestroke System Accurately Assesses Variety of Neurologic Syndromes
With 50% mimic rates in prior studies, telestroke consultation may be able to provide an early, accurate diagnosis to patients with stroke mimics, thus avoiding unnecessary treatments and transfers. However, data are lacking on...
Read More
Targeting CNS cells Key to Abrogate MS Progression
Prof. Tony Traboulsee talks to Physician’s Weekly about his study of tolebrutinib Presented at the...
Read MoreAAN 2021: Significant Discrepancy Found in General vs Neuroradiologists MRI Reporting of MS
Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI) and the support of dedicated multidisciplinary teams (MDTs). While decisions...
Read More
AAN 2021: Race May Affect Response to Anti-CD20 Therapy for MS, NMOSD
For patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD)...
Read More2021 AAN Annual Meeting Kick-Off!
Due to the COVID-19 pandemic, the 2021 American Academy of Neurology Annual Meeting, the world’s premier neurology meeting, will be held in a fully virtual format from April 17-22. It will include: Over 90 expert-led CME...
Read MoreAAN 2021: Identifying distinct cognitive phenotypes in multiple sclerosis
Cognitive impairment is a common and disabling feature of multiple sclerosis (MS), but a precise characterization of cognitive phenotypes in MS patients is still lacking. This study identified five cognitive phenotypes:...
Read MoreAAN 2021: Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis
The study team compared disability accrual in primary and secondary progressive multiple sclerosis (PPMS, SPMS) in the international MSBase cohort, using multivariable survival models, and applying objective diagnostic criteria...
Read MoreAAN 2021: Dual Tasking In Patients With MS
Patients with MS may have difficulty performing double task (DT) while walking or causing interference. More research is needed in order to define the role of disability degree in the severity of the interference produced in the...
Read MoreAAN 2021: Influencing And Optimizing The Management Of Patients With MS
Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI). As physicians, decisions are influenced by the reporting prowess of...
Read MorePhysQuiz Answers! AAN 2021: Multiple Sclerosis
Which of the following is a preliminary outcome of the retrospective, multi-center observational study in a cohort of Italian MS patients investigating the impact of disease-modifying treatments on COVID-19 course of disease?a)...
Read More- 1
- 2